Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Apr;4(4):755-62.
doi: 10.2215/CJN.02730608. Epub 2009 Apr 1.

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis

Patrick S Parfrey  1 , Maria Lauve, Dominick Latremouille-Viau, Patrick Lefebvre
Affiliations
Meta-Analysis

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis

Patrick S Parfrey et al. Clin J Am Soc Nephrol. 2009 Apr.

Abstract

Background and objectives: The purpose was to evaluate changes in the left ventricular mass index (LVMi) among anemic chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients treated with recombinant human erythropoietin (EPO).

Design, setting, participants, & measurements: A systematic review of the literature, reporting LVMi for patients before and after EPO therapy, was performed. The change in LVMi from baseline to the end of treatment was calculated and stratified by severity of anemia at baseline, target hemoglobin (Hb), and stage of kidney disease.

Results: Fifteen eligible studies involving 1731 patients were identified. Cohorts with severe anemia at baseline (<10 g/dl), when given EPO using a lower target level (Hb <or= 12 g/dl or Hct <or= 36%) experienced significant reductions in LVMi (-32.7 g/m(2); 95% CI: -49.4 to -16.1, P < 0.05). However, these studies lacked control groups. Cohorts with moderate anemia at baseline showed insignificant changes in LVMi: 5.3 g/m(2) (95% CI: -0.8 to 11.3) for patients assigned to a lower target, and -6.6 g/m(2) (95% CI: -17.2 to 4.0) for patients assigned to a higher target (Hb > 12 g/dl or Hct > 36%). The effect size was similar in direction for both CKD and ESRD cohorts.

Conclusions: Aggregated results from multiple studies suggest that in severe anemia conventional Hb targets for EPO therapy are associated with a reduction in LVMi, but that in moderate anemia target Hb above 12 g/dl does not have a significant beneficial impact on LVMi compared with conventional targets.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart showing how studies were selected.
Figure 2.
Figure 2.
(a) Study cohorts with severe anemia at baseline and lower target Hb. (b) Study cohorts with moderate anemia at baseline and lower target Hb. (c) Study cohorts with moderate anemia at baseline and higher target Hb.
See this image and copyright information in PMC

References

    1. Foley RN, Parfrey PS, Sarnak M: The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112–S115, 1998. [suppl] - PubMed
    1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489–495, 2005 - PubMed
    1. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Tranplant 11: 1277–1285, 1996 - PubMed
    1. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759–2767, 2001 - PubMed
    1. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11: 912–916, 2000 - PubMed

Publication types

MeSH terms